Real life evaluation of sodium-glucose cotransporter 2 inhibition in type 1 diabetes and the risk of diabetic ketoacidosis

Autor: Elisabeth B Stougaard, Peter L Kristensen, Urd Kielgast, Henrik U Andersen, Yasmin Hamid, Peter H Gæde, Esben Søndergaard, Gry H Dørflinger, Karen K Fjeldborg, Klavs W Hansen, Henrik H Thomsen, Thuraya M.J. Al-Imar, Michael Røder, Vikas S Sridhar, David Cherney, Peter Rossing, Frederik Persson

Publikováno v: Stougaard, E B, Kristensen, P L, Kielgast, U, Andersen, H U, Hamid, Y, Gæde, P H, Søndergaard, E, Dørflinger, G H, Fjeldborg, K K, Hansen, K W, Thomsen, H H, Al-Imar, T M J, Røder, M, Sridhar, V S, Cherney, D, Rossing, P & Persson, F 2022, ' Real life evaluation of sodium-glucose cotransporter 2 inhibition in type 1 diabetes and the risk of diabetic ketoacidosis ', Diabetes & vascular disease research, vol. 19, no. 5, pp. 14791641221130043 . https://doi.org/10.1177/14791641221130043
Stougaard, E B, Kristensen, P L, Kielgast, U, Andersen, H U, Hamid, Y, Gæde, P H, Søndergaard, E, Dørflinger, G H, Fjeldborg, K K, Hansen, K W, Thomsen, H H, Al-Imar, T M J, Røder, M, Sridhar, V S, Cherney, D, Rossing, P & Persson, F 2022, ' Real life evaluation of sodium-glucose cotransporter 2 inhibition in type 1 diabetes and the risk of diabetic ketoacidosis ', Diabetes & vascular disease research, vol. 19, no. 5 . https://doi.org/10.1177/14791641221130043

Background The indication for treatment of type 1 diabetes(T1D) with the sodium–glucose cotransporter 2 inhibitor (SGLT2i) dapagliflozin has been withdrawn in Europe likely because of concern for diabetic ketoacidosis (DKA). We calculated the incid

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1362b97ba69086d2c89615b716f65782
https://pubmed.ncbi.nlm.nih.gov/36262089